immuno oncology frontiers world miami


Patrick Tricoli

Dr Patrick Tricoli

CEO, Nanobiotix US

Before joining Synthélabo Recherche in 1991 as project leader in pharmaco-toxicology, Patrick Tricoli conducted research in neuropharmacology from 1986 to 1990 in both academic and industrial environment within CNRS/INSERM laboratories, Army Research Center and the Medical research Division of Lederle laboratories (today Wyeth Pharmaceuticals) in the United States. In 1996, he joint Synthélabo group headquarter to lead Research and Technology valorization activity to raise external public financing for innovative R&D and industrial projects at National and European level. He became, in 1999, director of Corporate Promotion of Innovation of Sanofi-Synthélabo within General Affairs division; he developed collaborative research programs, lead international Corporate Development action and the integration of Sanofi-Synthelabo within the European research and innovation Framework program.

After 2004, Patrick Tricoli within Sanofi-Aventis R&D led the Valorization and Innovation team managing up to 40 collaborative R&D projects in France, Germany and at European level. In 2007, appointed Global Deputy Head of Partnering and Innovation R&D Department, Patrick developed proactive scouting of external opportunities within major innovation clusters. He contributed to the integration of Sanofi-Aventis within “French competitiveness clusters” and R&D collaborations. He was also appointed within European Commission/European Pharmaceutical Industry Governance Task Force of the Innovative Medicines Initiative” (IMI), and set up the internal IMI office to implement the initiative at Sanofi-Aventis.

In Mars 2009, he took the lead within the new created External innovation department. The following years, Patrick implemented international scouting and partnering activities. In addition, he developed Sanofi strategy, positioning and company branding within Global External Innovation and partnering events in Europe, Asia Pacific and in the US.

Patrick Tricoli joint Nanobiotix team in September 2014 as VP Corporate Development and he is in charge of the Nanobiotix US affiliate, Nanobiotix Corp. Patrick is Doctor in Pharmaceutical Sciences, hold a Master degree in Pharmacology and Pharmacokinetic and an Executive MBA from ESCP Europe

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy